GeNeuro SA (EPA:GNRO)

France flag France · Delayed Price · Currency is EUR
0.0700
-0.0080 (-10.26%)
Apr 24, 2025, 1:17 PM CET
-95.10%
Market Cap 2.31M
Revenue (ttm) n/a
Net Income (ttm) -14.76M
Shares Out 29.60M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,038
Average Volume 58,273
Open 0.0780
Previous Close 0.0780
Day's Range 0.0700 - 0.0780
52-Week Range 0.0428 - 2.3500
Beta 0.73
RSI 47.00
Earnings Date May 2, 2025

About GeNeuro

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development progra... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 17
Stock Exchange Euronext Paris
Ticker Symbol GNRO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.